Convalescent plasma to treat COVID-19

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, non-transfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.

Original languageEnglish (US)
Pages (from-to)654-655
Number of pages2
Issue number6
StatePublished - Aug 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Convalescent plasma to treat COVID-19'. Together they form a unique fingerprint.

Cite this